Abstract
Background
During maintenance proton pump inhibitor (PPI) therapy, patients with gastroesophageal reflux disease (GERD) sometimes complain of upper gastrointestinal symptoms.
Aim
To evaluate upper gastrointestinal symptoms in patients on maintenance PPI therapy for erosive GERD or non-erosive reflux disease (NERD) without endoscopic mucosal breaks by using a new questionnaire.
Methods
At Gunma University Hospital over a 12-month period during 2011–2012, we enrolled 30 consecutive patients with erosive GERD and 46 patients with NERD. All patients had been on maintenance PPI therapy for more than 1 year. We used the modified frequency scale for the symptoms of GERD (mFSSG) questionnaire to assess upper gastrointestinal symptoms. We also asked patients about their satisfaction with maintenance therapy and whether they wished to change their current PPI.
Results
The NERD patients had significantly higher symptom scores than the erosive GERD patients. There was no difference in the treatment satisfaction rate between patients with erosive GERD and NERD, but more patients with NERD wanted to change their PPI therapy. There was no difference in the mFSSG score between NERD patients who wished to change their current PPI therapy and those who were satisfied with it.
Conclusions
During maintenance PPI therapy, upper gastrointestinal symptoms were more severe in NERD patients than in patients with erosive GERD. NERD patients often wished to change their PPI therapy, but this was not dependent on the severity of their upper GI symptoms.
Similar content being viewed by others
References
Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–20.
Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-esophageal reflux disease. Digestion. 1992;51(Suppl 1):59–67.
Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-esophageal reflux disease. Aliment Pharmacol Ther. 1995;9(Suppl 1):3–7.
Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short-term management of reflux oesophagitis. Cochrane Database Syst Rev. 2007;2:CD003244.
Chiba N, DeGara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptoms relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798–810.
Modlin IM, Hunt RH, Malfertheiner P, et al. Diagnosis and management of non-erosive reflux disease—the Vevey NERD Consensus Group. Digestion. 2009;80:74–88.
Kusano M, Shirai N, Yamaguchi K, et al. It is possible to classify non-erosive reflux disease (NERD) patients into endoscopically normal groups and minimal change groups by subjective symptoms and responsiveness to rabeprazole—a report from a study with Japanese patients. Dig Dis Sci. 2008;53:3082–94.
Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656–64.
Fass R, Shapiro M, Dekel R, Sewell J. Systematic Review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther. 2005;22:79–94.
Jones R, Armstrong D, Malfertheiner P, Ducrotte P. Does the treatment of gastroesophageal reflux disease (GERD) meet patients’ needs? Curr Med Res Opin. 2006;22:657–62.
Coron E, Hatlebakk JG, Galmiche JP. Medical therapy of gastroesophageal reflux disease. Curr Opin Gastroenterol. 2007;23:434–9.
Liker HR, Ducrotte P, Malfertheiner P. Unmet medical needs among patients with gastroesophageal reflux disease: a foundation for improving management in primary care. Dig Dis. 2009;27:62–7.
Weijenborg PW, Cremonini F, Smout AJPM, Bredenoord AJ. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24:747–57.
Kusano M, Hosaka H, Kawada A, et al. Development and evaluation of a modified frequency scale for the symptoms of gastroesophageal reflux disease to distinguish functional dyspepsia from non-erosive reflux disease. J Gastroenterol Hepatol. 2012;27:1187–91.
Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology. 1996;111:85–92.
Kawamura O, Hosaka H, Shimoyama Y, Kawada A, Kuribayashi S, Kusano M. A substantial percentage of suspected PPI-resistant NERD patients have primary esophageal motility disorders: results of high resolution manometry and 24-h esophageal impedance and pH monitoring. 2014 Accepted Abstracts, A-1425, DDW 2014.
Kusano M, Shimoyama Y, Kawamura O, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004;39:888–91.
Hershcovici T, Fass R. Nonerosive reflux disease (NERD)—an update. J Neurogastroenterol Motil. 2010;16:8–21.
Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite anti suppressive therapy: multicenter study using combined ambulatory impedance-pH monitoring. Gut. 2006;55:1398–402.
Armstrong D, Talley NJ, Lauritsen K, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther. 2004;20:413–21.
Iwakiri K, Kawami N, Tanaka Y, et al. Acid and non-acid reflux in Japanese patients with non-erosive reflux disease with persistent reflux symptoms, despite taking a double-dose of proton pump inhibitor: a study using combined pH-impedance monitoring. J Gastroenterol. 2009;44:708–12.
Furuta T, Shimatani T, Sugimoto M, et al. Investigation of pretreatment of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADE study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol. 2011;46:1273–83.
Fass R, Chey WD, Zakko SF, et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2009;29:1261–72.
Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol. 2008;103:20–6.
Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kjino M, Inatomi N. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther. 2011;337:797–804.
Quigley EM. Review article: gastric emptying in functional gastrointestinal disorders. Aliment Pharmacol Ther. 2004;20(Suppl):56–60.
Wu JC, Cheung CM, Wong VW, Sung JJ. Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis. Clin Gastroenterol Hepatol. 2007;5:690–5.
Miyamoto M, Nanabe N, Haruma K. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptoms of GERD (FSSG) on decision of treatment strategy. Intern Med. 2010;49:1469–76.
Miyamoto M, Haruma K, Takeuchi K, Kuwabara M. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics of proton pump inhibitor therapy. J Gastroenterol Hepatol. 2008;23:746–51.
Kusano M, Hongo M, Miwa H. Response to gastroesophageal reflux disease therapy: assessment at 4 weeks predicts response/non-response at 8 weeks. Digestion. 2012;85:282–7.
Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333:1106–10.
Patric L. Gastroesophageal reflux disease (GERD): a review of conventional and alternative treatments. Altern Med Rev. 2011;16:116–33.
Tominaga K, Iwakiri R, Fujimoto K, et al. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan. J Gastroenterol. 2012;47:284–92.
Tominaga K, Kato M, Takeda H et al. A randomized, placebo-controlled, double-blind clinical trial of Rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study. J Gastroenterol. 2014 Feb 18 (Epub ahead of print).
Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther. 2007;26:1333–44.
Bytzer P. What makes individuals with gastroesophageal reflux disease dissatisfied with their treatment? Clin Gastroenterol Hepatol. 2009;7:816–22.
Savarino E, Zentilin P, Mastracci L, et al. Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. J Gastroentrol. 2013;48:473–82.
Conflict of interest
Kusano M received lecture fees from Eisai Co., Ltd., Astellas Co., Ltd., and AstraZeneca Co., Ltd.. Motoyasu Kusano received commercial research funding from Eisai Co., Ltd., Astellas Co., Ltd., Daiichi-Sankyo Co., Ltd., and Given Imaging., Ltd. The following authors have nothing to declare: Osamu Kawamura, Hiroko Hosaka, Akiyo Kawada, Shikou Kuribayashi, Yasuyuki Shimoyama, Hidetoshi Yasuoka, Masafumi Mizuide, Taku Tomizawa, Toshihiko Sagawa, Ken Sato and Masanobu Yamada.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Kusano, M., Hosaka, H., Kawamura, O. et al. More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy. J Gastroenterol 50, 298–304 (2015). https://doi.org/10.1007/s00535-014-0972-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-014-0972-9